Strategy that connects market opportunity to responsible execution.
Four service areas structured around the decisions healthcare companies face when entering, expanding, or rebuilding commercial position in complex U.S. markets.
What USHSG is not
USHSG is not a marketing agency. It is a strategy group focused on clinical adoption, KOL development, research readiness, and commercialization support for healthcare companies where trust, evidence, workflow, and access matter.
Market Entry & Commercial Strategy
US Health Strategy Group maps the clinical and commercial landscape before building a directional strategy aligned to the product's cleared indication, evidence base, and organizational capacity. The output is a plan the organization can execute: a defined market, a clarified buyer, and a channel built for the actual sales environment.
Clinical setting analysis, buyer mapping, competitive context, and indication-specific segment prioritization.
Channel selection, sales motion recommendation, reimbursement landscape, and near-term market entry roadmap.
Coverage landscape, access barriers, CPT/billing context, and provider-level reimbursement considerations.
Competitive positioning, differentiation framework, and market timing analysis for key target accounts.
90-day and 12-month commercial roadmap with milestones, resource requirements, and decision gates.
VA procurement pathway, federal formulary access, and market entry strategy for the veteran health channel.
Adoption, Evidence & Innovation
The path from clinical interest to adoption requires connecting research design, evidence strategy, and workflow integration to a defined commercial goal, without conflating them or creating compliance exposure. US Health Strategy Group structures that path with clinical integrity intact from the first engagement.
Workflow integration pathway, training model, institutional adoption timeline, and barrier analysis.
Published evidence review, clinical claim audit, gap identification, and evidence-building priority recommendation.
Academic partnership identification, grant positioning, IRB-readiness, and research design framing.
Clinical workflow fit assessment, validation strategy, and responsible adoption pathway for digital and AI-enabled products.
Next-indication mapping, platform expansion framework, and clinical development priority analysis.
HCP education strategy, content framework, training platform design, and CME-adjacent program structure.
Commercial Execution & Strategic Advisory
US Health Strategy Group works with commercial leadership, sales teams, and executive teams to build the infrastructure a field organization can operate from: a segmented account model, a replicable sales motion, a defined objection framework, and a channel strategy aligned to the actual purchase environment. Founder-level and board-level advisory support are available as a defined engagement scope. The output is a commercial system, not a set of recommendations.
Call models, objection handling, clinical messaging, and account-tier priority frameworks for field teams.
Account segmentation, priority tiering, field coverage model, and target account activation plan.
Distribution, co-marketing, referral, and partnership framework for expanding commercial reach.
Structured advisory support for founders, boards, and independent advisors: commercial framing, investor readiness, milestone sequencing, and cross-functional alignment. Delivered as defined engagement scope, not open-ended retainer time.
Cross-functional audit of commercial infrastructure: sales ops, CRM, forecasting, and field alignment.
Category positioning, investor narrative, and market-facing messaging aligned to clinical and commercial reality.
KOL Strategy & Advisory Development
KOL infrastructure is a long-term commercial asset. US Health Strategy Group designs, maps, activates, and sustains physician and expert advisory networks built with compliance-informed guardrails from the start. Bona fide need, written scope, documented deliverables, FMV, independence, disclosure, and no volume or value linkage are all relevant controls. Client counsel determines final regulatory compliance under AKS, Stark, Open Payments, and applicable state law.
Identification, tiering, geographic coverage, and influence mapping for national, regional, and emerging KOLs.
Advisory board structure, speaker bureau framework, research collaboration design, and engagement SOPs.
Fair market value documentation, engagement contract framework, and Open Payments reporting structure. Designed for counsel review. FMV and written scopes reduce risk but are not a legal safe harbor under the Anti-Kickback Statute. Client counsel determines final AKS, Stark, and state-law compliance.
Onboarding, education, activation sequence, and ongoing engagement cadence for priority physician advisors.
Medical affairs-aligned communication framework, data dissemination strategy, and MSL/field medical interface.
Existing KOL network audit: coverage gaps, engagement quality, compliance posture, and activation effectiveness.
Start with the decision in front of you.
Describe the product, market, stage, and the decision in front of the team. US Health Strategy Group will recommend the right starting scope, from a focused readiness sprint to a full market-entry blueprint.